JP2007533733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533733A5 JP2007533733A5 JP2007509061A JP2007509061A JP2007533733A5 JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5 JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- betahistine
- pharmaceutical composition
- medicament
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 21
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 229960004536 betahistine Drugs 0.000 claims 9
- 229940001470 psychoactive drug Drugs 0.000 claims 9
- 239000004089 psychotropic agent Substances 0.000 claims 9
- 230000000561 anti-psychotic effect Effects 0.000 claims 8
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical group NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000004584 weight gain Effects 0.000 claims 6
- 235000019786 weight gain Nutrition 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 4
- 229960005017 olanzapine Drugs 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 239000003270 steroid hormone Substances 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 229940096699 bile acid sequestrants Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000005686 eating Nutrition 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL16159504A IL161595A0 (en) | 2004-04-22 | 2004-04-22 | Betahistine as a weight management agent |
| US67029005P | 2005-04-12 | 2005-04-12 | |
| PCT/IL2005/000440 WO2005101979A2 (en) | 2004-04-22 | 2005-04-21 | Method of food intake management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533733A JP2007533733A (ja) | 2007-11-22 |
| JP2007533733A5 true JP2007533733A5 (https=) | 2008-05-29 |
Family
ID=35197421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509061A Pending JP2007533733A (ja) | 2004-04-22 | 2005-04-21 | 食物摂取管理の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7737165B2 (https=) |
| EP (1) | EP1737454A4 (https=) |
| JP (1) | JP2007533733A (https=) |
| KR (1) | KR20060134041A (https=) |
| BR (1) | BRPI0506807A (https=) |
| CA (1) | CA2553309A1 (https=) |
| EA (1) | EA200601414A1 (https=) |
| IL (1) | IL176793A0 (https=) |
| NO (1) | NO20063221L (https=) |
| WO (1) | WO2005101979A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
| BRPI0506807A (pt) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | método de gerenciamento de consumo de alimento e composição farmacológica |
| WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| UA98938C2 (ru) * | 2006-06-16 | 2012-07-10 | Теракос, Инк. | Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1 |
| US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP3788877B1 (en) * | 2007-04-11 | 2024-08-07 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM |
| JP5513378B2 (ja) * | 2007-06-15 | 2014-06-04 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド | 治療化合物 |
| KR101621726B1 (ko) | 2008-05-27 | 2016-05-17 | 더 유니버시티 오브 멜버른 | 유스타키오관 기능장애 치료용 국소 약학적 조성물 |
| US20120115778A1 (en) * | 2009-07-15 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 |
| US20110021507A1 (en) * | 2009-07-22 | 2011-01-27 | Theracos, Inc. | Inhibiting antipsychotic-induced weight gain |
| JP2013507713A (ja) * | 2009-10-13 | 2013-03-04 | ネステク ソシエテ アノニム | 食物摂取を評定するシステム及びそのシステムを使用する方法 |
| TR201908514T4 (tr) | 2009-12-04 | 2019-07-22 | Alkermes Pharma Ireland Ltd | İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ |
| US20110143704A1 (en) | 2009-12-14 | 2011-06-16 | William Lorentz | Specialized dial a chip |
| US8778960B2 (en) * | 2010-08-23 | 2014-07-15 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US20140072936A1 (en) * | 2012-09-07 | 2014-03-13 | Patrick D. Herron | Method of Tracking Consumption and Associated Effects |
| ES2770978T3 (es) | 2013-05-24 | 2020-07-06 | Alkermes Pharma Ireland Ltd | Análogos de morfanos y morfinanos y métodos de uso |
| EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| RU2540911C2 (ru) * | 2013-06-11 | 2015-02-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами |
| DE102015202695A1 (de) * | 2015-02-13 | 2016-08-18 | Carl Zeiss Smt Gmbh | Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels |
| ES2969301T3 (es) * | 2017-02-02 | 2024-05-17 | Otolanum Ag | Composición intranasal que comprende betahistina |
| EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| KR20250154480A (ko) * | 2023-02-28 | 2025-10-28 | 바이오하벤 테라퓨틱스 리미티드 | 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1577871A (en) * | 1976-05-28 | 1980-10-29 | Unimed Inc | Prevention of myocardial infarction |
| JPS55154915A (en) * | 1979-05-21 | 1980-12-02 | Jiyan Sadeia Shieruki | Medicine mold |
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| DE69939027D1 (de) * | 1998-12-23 | 2008-08-14 | Maxim Pharm Inc | Synthese von histamin-dihydrochlorid |
| DE69911058T2 (de) | 1998-12-23 | 2004-06-03 | G.D. Searle Llc, Chicago | Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen |
| IT1309591B1 (it) | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | Composizioni a rilascio controllato di betaistina. |
| WO2000071106A2 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treating weight gain |
| WO2001066081A2 (de) * | 2000-03-08 | 2001-09-13 | Awd.Pharma Gmbh & Co.Kg | Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| WO2002087556A2 (en) | 2001-04-11 | 2002-11-07 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| US20030162824A1 (en) | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| AU2003266165A1 (en) | 2002-09-13 | 2004-04-30 | Hossein Dovlatabadi | Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
| BRPI0506807A (pt) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | método de gerenciamento de consumo de alimento e composição farmacológica |
| US20060039867A1 (en) | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
-
2005
- 2005-04-21 BR BRPI0506807-0A patent/BRPI0506807A/pt not_active IP Right Cessation
- 2005-04-21 EP EP05734836A patent/EP1737454A4/en not_active Withdrawn
- 2005-04-21 CA CA002553309A patent/CA2553309A1/en not_active Abandoned
- 2005-04-21 KR KR1020067015532A patent/KR20060134041A/ko not_active Ceased
- 2005-04-21 WO PCT/IL2005/000440 patent/WO2005101979A2/en not_active Ceased
- 2005-04-21 EA EA200601414A patent/EA200601414A1/ru unknown
- 2005-04-21 JP JP2007509061A patent/JP2007533733A/ja active Pending
- 2005-11-22 US US11/283,928 patent/US7737165B2/en not_active Expired - Lifetime
- 2005-11-22 US US11/283,865 patent/US20060084686A1/en not_active Abandoned
-
2006
- 2006-07-11 IL IL176793A patent/IL176793A0/en unknown
- 2006-07-11 NO NO20063221A patent/NO20063221L/no not_active Application Discontinuation
-
2007
- 2007-08-03 US US11/882,740 patent/US20080004322A1/en not_active Abandoned
- 2007-08-03 US US11/882,677 patent/US20080004324A1/en not_active Abandoned
- 2007-08-03 US US11/882,678 patent/US20080051439A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533733A5 (https=) | ||
| RU2355387C2 (ru) | Трансдермальный гранисетрон | |
| EP3731870B1 (en) | Liquid oral formulations for pde v inhibitors | |
| JP2008007519A5 (https=) | ||
| JP2014528474A5 (https=) | ||
| Quinn et al. | Novel methods of drug administration for the treatment and care of older patients | |
| CA2450366A1 (en) | Controlled heat induced rapid delivery of pharmaceuticals from skin depot | |
| ES2762113T3 (es) | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor | |
| JP2010530431A5 (https=) | ||
| JP2018520382A (ja) | 薬物の投与及び混合のための装置及び方法、並びにそのための適切な技法のトレーニング | |
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| US20200093737A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| CN103102348A (zh) | 噁二唑类化合物及其制备方法、药物组合物及其用途 | |
| WO2013173317A1 (en) | TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS | |
| US20160287549A1 (en) | Novel methods for treating neurodegenerative diseases | |
| US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| Frijlink | Benefits of different drug formulations in psychopharmacology | |
| JP2009539877A5 (https=) | ||
| EP1772149A1 (en) | Drug for prevention or treatment of diabetes | |
| JP2022508217A (ja) | Ｔａｓｋ－１およびｔａｓｋ－３チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用 | |
| JP2009506043A5 (https=) | ||
| CN102772414A (zh) | 治疗潮红的s-米氮平 | |
| WO2024107115A1 (en) | Methods of compounding an injectable drug into a film or wafer and systems thereof | |
| JP2021533192A (ja) | 薬剤を含む共晶溶媒、並びにその製造および使用方法 | |
| Babu et al. | Overview of formulation & evaluation of fast dissolving tablet: A promising tablet dosage form |